Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nucleolar RNA SNORD22 (also known as snoRNA U22 or U22) is a non-coding RNA belonging to the box C/D class of snoRNAs, primarily functioning as a guide for site-specific 2′-O-methylation of nucleotides within ribosomal RNA and possibly small nuclear RNA[2][1][3]. It is typically located in the nucleolus, the main site of snRNA and rRNA maturation, and is encoded within the introns of the U22 host gene in mammals[2]. Like other C/D box snoRNAs, SNORD22 contains characteristic sequence motifs (C box and D box), associates with ribonucleoprotein complexes including fibrillarin and other core proteins, and plays a crucial role in ribosome biogenesis and potentially regulation of alternative splicing, but it is not considered a conventional therapeutic target such as a receptor, enzyme, or transporter[2][5][1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nucleolar RNA SNORD22 (SNORD22).